{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:24:38Z","timestamp":1790915078854,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"ERDF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT","doi-asserted-by":"publisher","award":["UIDB\/50026\/2020"],"award-info":[{"award-number":["UIDB\/50026\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.intimp.2024.111826","type":"journal-article","created":{"date-parts":[[2024,3,10]],"date-time":"2024-03-10T21:44:04Z","timestamp":1710107044000},"page":"111826","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Distinct disease-modifying therapies are associated with different blood immune cell profiles in people with relapsing-remitting multiple sclerosis"],"prefix":"10.1016","volume":"131","author":[{"given":"Jo\u00e3o","family":"Canto-Gomes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1331-3909","authenticated-orcid":false,"given":"Daniela","family":"Boleixa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catarina","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Martins da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9897-0771","authenticated-orcid":false,"given":"In\u00e9s","family":"Gonz\u00e1lez-Su\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Cerqueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarida","family":"Correia-Neves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0282-9619","authenticated-orcid":false,"given":"Claudia","family":"Nobrega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2024.111826_b0005","unstructured":"The Multiple Sclerosis International Federation. Atlas of MS 2020. https:\/\/www.msif.org\/wp-content\/uploads\/2020\/10\/Atlas-3rd-Edition-Epidemiology-report-EN-updated-30-9-20.pdf (accessed 27 March 2023)."},{"issue":"1","key":"10.1016\/j.intimp.2024.111826_b0010","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","article-title":"Multiple sclerosis","volume":"4","author":"Filippi","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"2","key":"10.1016\/j.intimp.2024.111826_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.lpm.2021.104068","article-title":"Update on treatment in multiple sclerosis","volume":"50","author":"Callegari","year":"2021","journal-title":"Presse Med."},{"issue":"12","key":"10.1016\/j.intimp.2024.111826_b0020","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","article-title":"Treatment of multiple sclerosis: a review","volume":"133","author":"Hauser","year":"2020","journal-title":"Am. J. Med."},{"issue":"8","key":"10.1016\/j.intimp.2024.111826_b0025","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"J. Am. Med. Assoc."},{"issue":"20","key":"10.1016\/j.intimp.2024.111826_b0030","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.intimp.2024.111826_b0035","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1136\/jnnp-2014-307721","article-title":"Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy","volume":"86","author":"Tuohy","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.intimp.2024.111826_b0040","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1212\/WNL.0000000000000540","article-title":"Alemtuzumab: the advantages and challenges of a novel therapy in MS","volume":"83","author":"Menge","year":"2014","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.intimp.2024.111826_b0045","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaneurol.2017.0676","article-title":"Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab","volume":"74","author":"Baker","year":"2017","journal-title":"JAMA Neurol."},{"issue":"7","key":"10.1016\/j.intimp.2024.111826_b0050","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11940-021-00677-1","article-title":"Early aggressive treatment approaches for multiple sclerosis","volume":"23","author":"Simpson","year":"2021","journal-title":"Curr. Treat. Options. Neurol."},{"issue":"1","key":"10.1016\/j.intimp.2024.111826_b0055","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12010119","article-title":"Escalation vs. early intense therapy in multiple sclerosis","volume":"12","author":"Casanova","year":"2022","journal-title":"J Pers Med"},{"issue":"2","key":"10.1016\/j.intimp.2024.111826_b0060","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2174\/1871527317666180327122435","article-title":"Characterization of regulatory T-cells in multiple sclerosis patients treated with interferon Beta-1a","volume":"17","author":"Ebrahimimonfared","year":"2018","journal-title":"CNS Neurol. Disord. Drug Targets"},{"issue":"2","key":"10.1016\/j.intimp.2024.111826_b0065","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2249.2007.03555.x","article-title":"Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells","volume":"151","author":"Airas","year":"2008","journal-title":"Clin. Exp. Immunol."},{"issue":"1\u20132","key":"10.1016\/j.intimp.2024.111826_b0070","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jns.2008.07.007","article-title":"T-cells expressing natural killer (NK) receptors are altered in multiple sclerosis and responses to alpha-galactosylceramide are impaired","volume":"275","author":"O'Keeffe","year":"2008","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.intimp.2024.111826_b0075","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.3389\/fimmu.2019.01414","article-title":"What defines NK cell functional fate: phenotype or metabolism?","volume":"10","author":"Poznanski","year":"2019","journal-title":"Front. Immunol."},{"issue":"Pt 9","key":"10.1016\/j.intimp.2024.111826_b0080","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/brain\/awh219","article-title":"The regulatory role of natural killer cells in multiple sclerosis","volume":"127","author":"Takahashi","year":"2004","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.intimp.2024.111826_b0085","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.3390\/jcm9051450","article-title":"CD56bright natural killer cells: a possible biomarker of different treatments in multiple sclerosis","volume":"9","author":"Laroni","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.intimp.2024.111826_b0090","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.901165","article-title":"Low memory T cells blood counts and high Na\u00efve regulatory T cells percentage at relapsing remitting multiple sclerosis diagnosis","volume":"13","author":"Canto-Gomes","year":"2022","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2024.111826_b0095","doi-asserted-by":"crossref","DOI":"10.3390\/cells12030439","article-title":"People with primary progressive multiple sclerosis have a lower number of central memory T cells and HLA-DR","volume":"12","author":"Canto-Gomes","year":"2023","journal-title":"Cells"},{"issue":"9","key":"10.1016\/j.intimp.2024.111826_b0100","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1002\/hbm.23242","article-title":"The functional connectome of cognitive reserve","volume":"37","author":"Marques","year":"2016","journal-title":"Hum. Brain Mapp."},{"key":"10.1016\/j.intimp.2024.111826_b0105","doi-asserted-by":"crossref","unstructured":"J. Cohen, Statistical power analysis for the behavioral sciences, Academic Press, 2013.","DOI":"10.4324\/9780203771587"},{"issue":"1\u20132","key":"10.1016\/j.intimp.2024.111826_b0110","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2014.12.020","article-title":"Variation in the human immune system is largely driven by non-heritable influences","volume":"160","author":"Brodin","year":"2015","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.intimp.2024.111826_b0115","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nri.2016.125","article-title":"Human immune system variation","volume":"17","author":"Brodin","year":"2017","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2024.111826_b0120","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","article-title":"Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis","volume":"33","author":"Chun","year":"2010","journal-title":"Clin. Neuropharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2024.111826_b0125","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41598-019-57114-2","article-title":"Pre-treatment T-cell subsets associate with fingolimod treatment responsiveness in multiple sclerosis","volume":"10","author":"Ghadiri","year":"2020","journal-title":"Sci. Rep."},{"issue":"15","key":"10.1016\/j.intimp.2024.111826_b0130","doi-asserted-by":"crossref","first-page":"e1724","DOI":"10.1212\/WNL.0000000000007262","article-title":"Effect of dimethyl fumarate on lymphocytes in RRMS: implications for clinical practice","volume":"92","author":"Mehta","year":"2019","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.intimp.2024.111826_b0135","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.4049\/jimmunol.1601532","article-title":"Dimethyl fumarate selectively reduces memory T cells and shifts the balance between Th1\/Th17 and Th2 in multiple sclerosis patients","volume":"198","author":"Wu","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2024.111826_b0140","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.3389\/fimmu.2019.01204","article-title":"Alemtuzumab in multiple sclerosis: short- and long-term effects of immunodepletion on the peripheral Treg compartment","volume":"10","author":"Haas","year":"2019","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2024.111826_b0145","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1002\/art.21255","article-title":"Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: Involvement of impaired integrin activation and immunologic synapse formation","volume":"52","author":"Zeyda","year":"2005","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.intimp.2024.111826_b0150","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s40265-014-0212-x","article-title":"Teriflunomide and its mechanism of action in multiple sclerosis","volume":"74","author":"Bar-Or","year":"2014","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.intimp.2024.111826_b0155","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a032003","article-title":"Interferon \u03b2 for multiple sclerosis","volume":"8","author":"Jakimovski","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"6","key":"10.1016\/j.intimp.2024.111826_b0160","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/11591110-000000000-00000","article-title":"The mechanism of action of interferon-\u03b2 in relapsing multiple sclerosis","volume":"25","author":"Kieseier","year":"2011","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.intimp.2024.111826_b0165","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jamaneurol.2013.598","article-title":"Natalizumab","volume":"70","author":"Rudick","year":"2013","journal-title":"JAMA Neurol."},{"issue":"4","key":"10.1016\/j.intimp.2024.111826_b0170","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1586\/14737175.4.4.571","article-title":"Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS","volume":"4","author":"Rudick","year":"2004","journal-title":"Expert Rev. Neurother."},{"issue":"9","key":"10.1016\/j.intimp.2024.111826_b0175","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"Placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.intimp.2024.111826_b0180","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.4049\/jimmunol.145.10.3247","article-title":"Differential expression of homing-associated adhesion molecules by T cell subsets in man","volume":"145","author":"Picker","year":"1990","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2024.111826_b0185","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00401-017-1744-4","article-title":"Phenotypic and functional characterization of T cells in white matter lesions of multiple sclerosis patients","volume":"134","author":"van Nierop","year":"2017","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.intimp.2024.111826_b0190","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jns.2019.01.007","article-title":"Factors associated with dimethyl fumarate-induced lymphopenia","volume":"398","author":"Sainz de la Maza","year":"2019","journal-title":"J. Neurol. Sci."},{"issue":"34","key":"10.1016\/j.intimp.2024.111826_b0195","doi-asserted-by":"crossref","first-page":"12474","DOI":"10.1073\/pnas.1406240111","article-title":"KLRG+ invariant natural killer T cells are long-lived effectors","volume":"111","author":"Shimizu","year":"2014","journal-title":"PNAS"},{"issue":"1","key":"10.1016\/j.intimp.2024.111826_b0200","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12974-020-01847-9","article-title":"Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis","volume":"17","author":"Gilmore","year":"2020","journal-title":"J. Neuroinflammation"},{"issue":"1","key":"10.1016\/j.intimp.2024.111826_b0205","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40263-021-00875-0","article-title":"Impact of Natural Killer (NK) cells on immune reconstitution, and their potential as a biomarker of disease activity in alemtuzumab-treated patients with relapsing remitting multiple sclerosis: an observational study","volume":"36","author":"Palmeri","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.intimp.2024.111826_b0210","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.imlet.2016.11.015","article-title":"In vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanoma","volume":"181","author":"Gandoglia","year":"2017","journal-title":"Immunol. Lett."},{"issue":"6","key":"10.1016\/j.intimp.2024.111826_b0215","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2217\/cer-2020-0267","article-title":"Efficacy classification of modern therapies in multiple sclerosis","volume":"10","author":"Samjoo","year":"2021","journal-title":"J. Comp. Eff. Res."},{"issue":"1","key":"10.1016\/j.intimp.2024.111826_b0220","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1212\/01.WNL.0000101724.93433.00","article-title":"Change in MS-related disability in a population-based cohort: a 10-year follow-up study","volume":"62","author":"Pittock","year":"2004","journal-title":"Neurology"}],"updated-by":[{"DOI":"10.1016\/j.intimp.2024.113555","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,12,25]],"date-time":"2024-12-25T00:00:00Z","timestamp":1735084800000}}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924003448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924003448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:56:38Z","timestamp":1778619398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924003448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":44,"alternative-id":["S1567576924003448"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.111826","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.07.20.549852","asserted-by":"object"}]},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distinct disease-modifying therapies are associated with different blood immune cell profiles in people with relapsing-remitting multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.111826","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111826"}}